Encompass Health Co. (NYSE:EHC) Shares Bought by Bahl & Gaynor Inc.

Bahl & Gaynor Inc. grew its holdings in shares of Encompass Health Co. (NYSE:EHC) by 76.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 32,510 shares of the company’s stock after purchasing an additional 14,054 shares during the period. Bahl & Gaynor Inc.’s holdings in Encompass Health were worth $2,789,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Principal Securities Inc. acquired a new position in Encompass Health in the fourth quarter worth approximately $25,000. Oakworth Capital Inc. bought a new stake in shares of Encompass Health during the 2nd quarter worth $40,000. Parallel Advisors LLC boosted its stake in shares of Encompass Health by 192.3% during the 4th quarter. Parallel Advisors LLC now owns 573 shares of the company’s stock worth $38,000 after acquiring an additional 377 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Encompass Health by 31.9% in the 1st quarter. GAMMA Investing LLC now owns 616 shares of the company’s stock worth $51,000 after acquiring an additional 149 shares during the last quarter. Finally, Daiwa Securities Group Inc. acquired a new stake in shares of Encompass Health during the second quarter worth $60,000. Institutional investors and hedge funds own 97.25% of the company’s stock.

Encompass Health Trading Up 0.1 %

Shares of NYSE:EHC opened at $91.72 on Thursday. The firm has a fifty day moving average of $89.01 and a two-hundred day moving average of $84.45. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 1.08. Encompass Health Co. has a 12-month low of $57.55 and a 12-month high of $94.38. The firm has a market capitalization of $9.23 billion, a P/E ratio of 24.79, a price-to-earnings-growth ratio of 1.40 and a beta of 0.88.

Encompass Health (NYSE:EHC) last released its quarterly earnings data on Monday, August 5th. The company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.10. Encompass Health had a return on equity of 17.83% and a net margin of 7.88%. The firm had revenue of $1.30 billion during the quarter, compared to analysts’ expectations of $1.30 billion. During the same quarter last year, the firm earned $0.95 earnings per share. The business’s revenue for the quarter was up 9.6% on a year-over-year basis. On average, equities analysts expect that Encompass Health Co. will post 4.17 EPS for the current fiscal year.

Encompass Health Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Tuesday, October 1st will be paid a $0.17 dividend. This is a boost from Encompass Health’s previous quarterly dividend of $0.15. The ex-dividend date of this dividend is Tuesday, October 1st. This represents a $0.68 annualized dividend and a dividend yield of 0.74%. Encompass Health’s payout ratio is presently 18.38%.

Insider Buying and Selling

In other Encompass Health news, CFO Douglas E. Coltharp sold 12,260 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $86.34, for a total value of $1,058,528.40. Following the completion of the sale, the chief financial officer now directly owns 136,227 shares of the company’s stock, valued at $11,761,839.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. Truist Financial lifted their price target on Encompass Health from $100.00 to $104.00 and gave the stock a “buy” rating in a research note on Thursday, August 15th. Leerink Partnrs raised shares of Encompass Health to a “strong-buy” rating in a research report on Wednesday, July 10th. Stephens restated an “overweight” rating and issued a $105.00 price target on shares of Encompass Health in a research report on Tuesday, August 6th. Barclays decreased their price objective on shares of Encompass Health from $113.00 to $109.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Finally, Leerink Partners started coverage on Encompass Health in a report on Wednesday, July 10th. They issued an “outperform” rating and a $100.00 target price for the company. Nine analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $100.38.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.